Clinical Trials Logo

COVID-19 clinical trials

View clinical trials related to COVID-19.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04603651 No longer available - COVID-19 Clinical Trials

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

NCT ID: NCT04372368 No longer available - COVID-19 Clinical Trials

Convalescent Plasma for the Treatment of Patients With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access program will provide access to COVID-19 convalescent plasma 150 or more individuals with moderate to severe or life-threatening manifestations of COVID-19, or documented to be at high risk of developing such manifestations at participating hospitals in Colorado.COVID-19 convalescent plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19. Convalescent plasma collected from individuals who have recovered from COVID-19 contains antibodies to SARS-CoV-2. Preliminary evidence and data collected during other respiratory virus outbreaks (including the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic) suggest that the antibodies in convalescent plasma may be effective in fighting the infection.

NCT ID: NCT04358588 No longer available - COVID-19 Clinical Trials

Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

The search for novel therapies to address the ongoing coronavirus (COVID-19) pandemic is ongoing. No proven therapies have been identified to prevent progression of the virus. Preliminary data suggest that inhaled nitric oxide (iNO) could have benefit in preventing viral progression and reducing reliance on supplemental oxygen and ventilator support. Expanded access allows for iNO to be delivered via the portable INOpulse delivery system for the treatment of COVID-19.

NCT ID: NCT04358211 No longer available - COVID-19 Clinical Trials

Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

I. Study Design: This is a single-arm feasibility study to assess the safety and efficacy of anti-SARS-CoV-2 convalescent plasma (CP) in 1. intubated, mechanically ventilated patients with confirmed COVID-19 pneumonia by chest X-ray or chest CT. 2. hospitalized patients with acute respiratory symptoms between 3 and 7 days after the onset of symptoms, with COVID-19. II. Study Population: 1. Population 1: Mechanically ventilated intubated COVID-19 patients aged 18 years or older. 2. Population 2: Hospitalized COVID-19 patients aged ≥18 years of age with respiratory symptoms within 3 to 7 days from the beginning of illness. III. Study Agent: SARS-CoV-2 convalescent plasma (1-2 units; ~200-400 mL at neutralization antibody titer >1:160.

NCT ID: NCT04355494 No longer available - COVID-19 Clinical Trials

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This protocol provides access to eculizumab treatment for participants with severe COVID-19.

NCT ID: NCT04338347 No longer available - COVID-19 Clinical Trials

CAP-1002 in Severe COVID-19 Disease

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in critical condition as indicated by life support measurements. Eligible subjects will receive open-label intravenous administration of investigational product (CAP-1002) containing 150 million allogeneic Cardiosphere-Derived Cells (CDCs). CAP-1002 administration will be conducted at the investigative site on Day 1 and weekly up to a maximum of 4 doses, based on clinical course. Subjects will complete protocol assessments at Screening; Day 1; Weeks 1-3; and Follow-up by phone 30 and 90 days after the last infusion. Baseline assessments will be conducted prior to first infusion on Day 1. The patient will be observed during the lengths of hospitalization and monitored for outcome and safety. Safety and outcome data will be collected and reported at the conclusion of treatment and follow-up.